Jacob Chacko Purchases 76,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Rating) CEO Jacob Chacko acquired 76,072 shares of the firm’s stock in a transaction dated Friday, May 13th. The shares were acquired at an average price of $2.82 per share, for a total transaction of $214,523.04. Following the acquisition, the chief executive officer now directly owns 802,652 shares of the company’s stock, valued at $2,263,478.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jacob Chacko also recently made the following trade(s):

• On Wednesday, May 11th, Jacob Chacko acquired 304,574 shares of ORIC Pharmaceuticals stock. The shares were acquired at an average price of $2.90 per share, for a total transaction of $883,264.60.
• On Friday, March 25th, Jacob Chacko acquired 50,000 shares of ORIC Pharmaceuticals stock. The shares were acquired at an average price of $4.54 per share, for a total transaction of $227,000.00.
• On Wednesday, March 23rd, Jacob Chacko acquired 257,127 shares of ORIC Pharmaceuticals stock. The shares were acquired at an average price of $4.98 per share, for a total transaction of $1,280,492.46.

Shares of ORIC opened at $2.81 on Friday. The stock’s 50-day moving average is $4.86 and its two-hundred day moving average is $10.08. ORIC Pharmaceuticals, Inc. has a 12 month low of $2.62 and a 12 month high of $26.70.

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Rating) last issued its quarterly earnings data on Monday, March 21st. The company reported ($0.58) EPS for the quarter, hitting analysts’ consensus estimates of ($0.58). During the same period last year, the firm posted ($0.84) EPS. As a group, equities research analysts predict that ORIC Pharmaceuticals, Inc. will post -2.44 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC lifted its stake in shares of ORIC Pharmaceuticals by 12.2% during the third quarter. EcoR1 Capital LLC now owns 3,468,944 shares of the company’s stock worth $72,536,000 after purchasing an additional 376,726 shares in the last quarter. BlackRock Inc. lifted its stake in shares of ORIC Pharmaceuticals by 6.2% during the third quarter. BlackRock Inc. now owns 2,410,542 shares of the company’s stock worth $50,406,000 after purchasing an additional 140,232 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of ORIC Pharmaceuticals by 16.8% during the fourth quarter. Victory Capital Management Inc. now owns 1,805,717 shares of the company’s stock worth $26,544,000 after purchasing an additional 259,394 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of ORIC Pharmaceuticals by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,644,019 shares of the company’s stock worth $8,779,000 after acquiring an additional 13,981 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of ORIC Pharmaceuticals by 20.0% in the fourth quarter. State Street Corp now owns 1,271,828 shares of the company’s stock worth $18,696,000 after acquiring an additional 211,929 shares in the last quarter. Institutional investors own 89.66% of the company’s stock.

A number of research analysts recently weighed in on ORIC shares. HC Wainwright cut ORIC Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, March 25th. Guggenheim downgraded ORIC Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 22nd. Citigroup raised ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.00 to $10.00 in a research report on Monday, April 4th. Zacks Investment Research downgraded ORIC Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 30th. Finally, Oppenheimer downgraded ORIC Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 22nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $23.46.

ORIC Pharmaceuticals Company Profile (Get Rating)

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations.

See Also